Narrow-band Ultraviolet B Treatment Boosts Serum 25-hydroxyvitamin D in Patients with Psoriasis on Oral Vitamin D Supplementation
ACTA Dermato-Venereologica doi: 10.2340/00015555-1685
Meri J. Ala-Houhala, Toni Karppinen, Katja Vähävihu, Hannu Kautiainen, Yvonne Dombrowski, Erna Snellman, Jürgen Schauber, Timo Reunala
Department of Dermatology, Tampere University Hospital, FIN-33521 Tampere, Finland
A course of treatment with narrow-band ultraviolet B (NB-UVB) improves psoriasis and increases serum 25-hydroxyvitamin D (25(OH)D). In this study 12 patients with psoriasis who were supplemented with oral cholecalciferol, 20 µg daily, were given a course of NB-UVB and their response measured. At baseline, serum 25(OH)D was 74.14 ± 22.9 nmol/l. At the 9th exposure to NB-UVB 25(OH)D had increased by 13.2 nmol/l (95% confidence interval (95% CI) 7.2–18.4) and at the 18th exposure by 49.4 nmol/l (95% CI 35.9–64.6) above baseline. Psoriasis Area Severity Index score improved from 8.7 ± 3.5 to 4.5 ± 2.0 (p < 0.001). At baseline, psoriasis lesions showed low vitamin D metabolizing enzyme (CYP27A1, CYP27B1) and high human β-defensin-2 mRNA expression levels compared with those of the healthy subjects. In conclusion, NB-UVB treatment significantly increases serum 25(OH)D in patients with psoriasis who are taking oral vitamin D supplementation, and the concentrations remain far from the toxicity level. Healing psoriasis lesions show similar mRNA expression of vitamin D metabolizing enzymes, but higher antimicrobial peptide levels than NB-UVB-treated skin in healthy subjects.
Fig. 2.
- (A) CYP27A1 mRNA,
- (B) CYP27B1 mRNA and
- (C) cathelicidin mRNA
expression levels in skin lesions of patients with psoriasis (n = 12) and normal skin of healthy subjects (n = 13) before and at 9th (after) narrow-band ultraviolet B (NB-UVB) exposure.
Before NB-UVB course the CYP27A1 and CYP27B1 levels are significantly lower (p < 0.001), but the cathelidicin levels do not differ (p = 0.34) in the patients with psoriasis compared with the healthy subjects.
NB-UVB exposure did not change CYP27A1 mRNA, CYP27B1 mRNA or cathelidicin mRNA levels in the patients with psoriasis (A: p = 0.17; B: p = 0.070; C: p = 0.88) but the decrease is significant (A: p< 0.001; B: p = 0.002; C: p< 0.001) in the healthy subjects.
PDF is attached at the bottom of this page
See also VitaminDWiki
- Psoriasis category listing with associated searches
- Molecular reason that UVB treats psoriasis – Mar 2011
- Ultraviolet light (which produces vitamin D) decreased the use of psoriasis drugs for a year – Aug 2017
63 items in CYP27B1 category Pages listed in BOTH Psoriasis AND UV
- Best psoriasis treatment was combo of Vitamin D, UVA, and Calcium – meta-analysis Jan 2022
- UV has treated psoriasis for over a century, guidelines finally agreed upon – Aug 2019
- Ultraviolet light (which produces vitamin D) decreased the use of psoriasis drugs for a year – Aug 2017
- Phototherapy and vitamin D – Sept 2016
- Psoriasis decreased and vitamin D increased with home UV lamp – March 2015
- NB UVB increased vitamin D levels while decreasing psoriasis and CYP27A1 – March 2014
- UVB effects on genes of those with and without Psoriasis – April 2014
- Psoriasis treatment by narrowband UV B – review Nov 2010
- UV produces more than vitamin D – Aug 2011
7626 visitors, last modified 07 Oct, 2019,